Establishing an accepted standard therapy in T-cell lymphomas remains elusive. This is, in part, due to the heterogeneity of the diseases as well as the too often suboptimal responses to commonly used upfront treatment strategies such as CHOP. Dr. Horwitz will review the current commonly used approaches highlighting where they are successful and where they appear inadequate. Increasingly, active agents and strategies in the relapsed setting (e.g., epigenetic modifiers, antibody drug conjugates, molecular targets, and checkpoint inhibitors) are providing additional treatment options at relapse as well as informing strategies for subtype-specific approaches in the upfront setting. Dr. Horwitz will review data for these newer approaches and how they are impacting current clinical trials.
Steven M. Horwitz
Active, International, Emeritus, and Honorary Members
Associate, International Associate, Student, and Resident Members